MM&M

Cytokinetics recounts lessons from failed ALS drug in a book

In the spring of 2023, Cytokinetics announced a pivot. Following the failure of ALS drug candidate reldesemtiv in a late-stage trial, the California-based biotech said it would focus its resources on ...
STAT

ALS patient lived with a brain-computer interface for 7 years. Here’s what researchers learned

O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming to STAT, she worked at WNYC’s Radiolab and Scientific American, and her ...